| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Ve vztahu k hlavnímu problému byly probírány a diskutovány různé oblasti medicínského zájmu, zejména: Antiepileptika - modelování a simulace v pediatrii. Bereme v úvahu adherenci nemocného k M and S? Thiopuriny jako antikancerozní látky. Simulace s využitím mechanistického modelu: vyhodnocení individuálního rizika. EMI-CD-Evropská iniciativa modelující potlačování choroby. Úloha biosimulace a Evropské BioSim sítě pro výzkum a vývoj léčiv. Antikoagulancia- modelování koagulace a jeho využití v klinickém rozhodování. TDM u novorozenců v klinickém stavu. Cílem jednání byla implementace softwaru a vymezení kritérií pro orgánové poškození. Simulace patologických podmínek byla vytvořena pro vyhodnocení individuálního rizika, které by vyžadovalo úpravu dávkování léčiv. (cs)
- Different topics were selected and discussed in relation to the main focus, especially: Antiepileptic drugs - pediatric modelling and simulation. Taking patients adherence into account in M and S. Thiopurines as anticancer drugs. Simulations using mechanistic model: Individual risk assessment. EMI-CD-European modeling initiative combating complex diseases. Role of Biosimulation and European BioSim Network in Drug Research and Development. Anticoagulation drugs- modeling of blood coagulation and the application to clinical decision making. TDM of gentamicin in neonates critically ill. After definition of the organ safety criterion and software implementation, simulations were performed in order to assess the individual risk which could involve a dose adjustment.
- Different topics were selected and discussed in relation to the main focus, especially: Antiepileptic drugs - pediatric modelling and simulation. Taking patients adherence into account in M and S. Thiopurines as anticancer drugs. Simulations using mechanistic model: Individual risk assessment. EMI-CD-European modeling initiative combating complex diseases. Role of Biosimulation and European BioSim Network in Drug Research and Development. Anticoagulation drugs- modeling of blood coagulation and the application to clinical decision making. TDM of gentamicin in neonates critically ill. After definition of the organ safety criterion and software implementation, simulations were performed in order to assess the individual risk which could involve a dose adjustment. (en)
|
| Title
| - COST akce B25 - Farmako-toxikokinetika a dynamika na fyziologickém základě. Od modelů k jednotlivým nemocným (cs)
- COST action B25 - Physiologically based pharmaco-toxico-kinetics and dynamics: expert meeting on %22From models to individual patients%22 (from in silico to bedside)
- COST action B25 - Physiologically based pharmaco-toxico-kinetics and dynamics: expert meeting on %22From models to individual patients%22 (from in silico to bedside) (en)
|
| skos:prefLabel
| - COST akce B25 - Farmako-toxikokinetika a dynamika na fyziologickém základě. Od modelů k jednotlivým nemocným (cs)
- COST action B25 - Physiologically based pharmaco-toxico-kinetics and dynamics: expert meeting on %22From models to individual patients%22 (from in silico to bedside)
- COST action B25 - Physiologically based pharmaco-toxico-kinetics and dynamics: expert meeting on %22From models to individual patients%22 (from in silico to bedside) (en)
|
| skos:notation
| - RIV/00216208:11150/08:00007138!RIV09-MSM-11150___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| - P(1P05OC061), P(1P05OC062), P(1P05OC066)
|
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11150/08:00007138
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - modelling; pharmaco-toxicokinetics; pharmacodynamics; in silico (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...v/mistoKonaniAkce
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...ocetUcastnikuAkce
| |
| http://linked.open...nichUcastnikuAkce
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...iv/statKonaniAkce
| |
| http://linked.open...iv/tvurceVysledku
| - Anzenbacher, Pavel
- Martínková, Jiřina
|
| http://linked.open...vavai/riv/typAkce
| |
| http://linked.open.../riv/ukonceniAkce
| |
| http://linked.open.../riv/zahajeniAkce
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)